Judith Klimovsky
Director/Board Member chez BIO-TECHNE CORPORATION
Fortune : 3 M $ au 31/03/2024
Postes actifs de Judith Klimovsky
Sociétés | Poste | Début | Fin |
---|---|---|---|
GENMAB A/S | Corporate Officer/Principal | 09/02/2017 | - |
BIO-TECHNE CORPORATION | Director/Board Member | 24/04/2024 | - |
Independent Dir/Board Member | 24/04/2024 | - |
Historique de carrière de Judith Klimovsky
Anciens postes connus de Judith Klimovsky
Sociétés | Poste | Début | Fin |
---|---|---|---|
BELLICUM PHARMACEUTICALS, INC. | Director/Board Member | 20/12/2018 | 23/02/2024 |
NOVARTIS AG | Corporate Officer/Principal | 01/05/2009 | 01/02/2017 |
Novartis Pharma AG
Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | Corporate Officer/Principal | 01/01/2009 | 01/01/2017 |
Formation de Judith Klimovsky
University of Buenos Aires School of Medicine | Doctorate Degree |
Statistiques
Internationale
Etats-Unis | 3 |
Suisse | 3 |
Danemark | 2 |
Opérationnelle
Corporate Officer/Principal | 3 |
Director/Board Member | 2 |
Doctorate Degree | 1 |
Sectorielle
Health Technology | 6 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 3 |
---|---|
BIO-TECHNE CORPORATION | Health Technology |
NOVARTIS AG | Health Technology |
GENMAB A/S | Health Technology |
Entreprise privées | 2 |
---|---|
Bellicum Pharmaceuticals, Inc.
Bellicum Pharmaceuticals, Inc. BiotechnologyHealth Technology Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. Its product candidates include BPX-601, BPX-603, and Rivo-cel (rivogenlecleucel, formerly known as BPX-501). The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX. | Health Technology |
Novartis Pharma AG
Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | Health Technology |
- Bourse
- Insiders
- Judith Klimovsky
- Expérience